Detailed Narrative
Overall Performance and Strategic Pillars
Strides Pharma delivered consistent growth over the last three years, with overall revenue CAGR of approximately 12% and EBITDA compounding at 26%. This performance was driven by a clear focus on geographical diversification, profitability, and balance sheet strength. For FY26, the company reported a revenue of INR 48,587 million, representing a 6.4% YoY growth, with EBITDA reaching INR 925 crores (19% margin) and operational PAT of INR 518 crores (50% YoY growth).
Geographical Diversification and Ex-U.S. Market Growth
Ex-U.S. markets have emerged as a significant growth driver, delivering a robust 21% growth in FY26 and achieving a 19% CAGR over the last three years. The Ex-U.S. business scaled significantly from $40 million per quarter in Q1 FY24 to $70 million per quarter in Q4 FY26. This structural shift has increased Ex-U.S. contribution to nearly 50% of total revenue in Q4 FY26, reducing single-market dependency and building a more resilient portfolio.
U.S. Market Dynamics and Portfolio Management
The U.S. business recorded $284 million in FY26 and $70 million in Q4, with performance impacted by a weaker flu season and lower-than-expected allocations for controlled substances. The company launched 6 new products and exited 9 non-profitable ones, reinforcing its focus on portfolio quality and profitability. Targeted investments of INR 2,500 million ($30 million) over 24 months in R&D and IP are expected to yield benefits starting from the second half of FY27.
Complex Generics Pipeline and Future Growth Drivers
Strides' pipeline is strategically shifting towards more differential programs, including nasal sprays, transdermal patches, and films. A second nasal spray was filed in May '26, with commercialization for the first nasal spray expected in another 12 months. The bulk of revenues from these complex generics are anticipated to contribute meaningfully from FY28 and FY29 onwards, with filings for patches and thin films expected within the next 12-18 months.
Capital Allocation, Debt Reduction, and ROCE Improvement
The company invested INR 418 crores in growth capital in FY26, comprising INR 236 crores in tangible capex for nasal spray capabilities and Ex-U.S. expansion, and INR 182 crores in intangible investments for global product rights and ERP upgrades. Net debt reduced by INR 197 crores (constant currency), bringing the net debt to EBITDA ratio to 1.55x in FY26 from 1.9x last year. ROCE improved significantly to 15.76% for FY26, up from single digits two years prior.
Sandoz Acquisition and African Market Strategy
The acquisition of certain products from Sandoz in February '26 is expected to fructify in H2 FY27 (October-March), significantly strengthening Strides' presence in sub-Saharan Africa. This deal, combined with the existing portfolio, aims to position the company as a leading pharmaceutical player in the region. The strategy focuses on increasing the share of branded business, particularly in markets like Francophone Africa, to drive sustainable growth and margin resilience.
Outlook and Long-Term Profitability Aspirations
Management reiterated its long-term aspiration to achieve EBITDA margins upwards of 20% and gross margins in the 58-60% range. The company aims for U.S. revenue of $375-400 million by FY28 and plans R&D spend of $20-25 million annually for the next two years. Despite external challenges🌐, Strides remains committed to operational discipline and expects growth to accelerate from H2 FY27, with a dividend of INR 5 per share recommended by the Board.